eFFECTOR Therapeutics, Inc. (EFTR) Research

eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is currently undergoing a Phase 2b clinical study for patients diagnosed with metastatic non-small cell lung cancer. Furthermore, eFFECTOR is progressing with Zotatifin, another small-molecule therapeutic designed to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 2 clinical trials, exploring its efficacy in treating different solid tumors. A strategic alliance with Pfizer Inc. supports eFFECTOR's work on developing additional eIF4E inhibitors. Founded in 2012, eFFECTOR Therapeutics, Inc. maintains its operational base in Solana Beach, California.

Market snapshot

Symbol
EFTR
Price
$0.00
Day change
0.00%
Market cap
$941.0
P/E ratio
-0.00x
52-week range
0.0002-0.01
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$5.50

Peer companies

  • Adynxx, Inc. (ADYX)
  • Adhera Therapeutics, Inc. (ATRX)
  • ContraFect Corporation (CFRXQ)
  • DMK Pharmaceuticals Corporation (DMKPQ)
  • IMV Inc. (IMVIF)
  • BioELife Corp. (LITH)
  • Omnimmune Holdings, Inc. (OMMH)
  • OncoSec Medical Incorporated (ONCSQ)

Recent insider activity

  • Loewy Caroline M — A-Award (800 shares) on 2024-06-13
  • Klencke Barbara — A-Award (800 shares) on 2024-06-13
  • Ehrlich Christopher B — A-Award (800 shares) on 2024-06-13
  • Harrington-Smith Kristen — A-Award (800 shares) on 2024-06-13
  • Gallagher Brian M. Jr. — A-Award (800 shares) on 2024-06-13

Open eFFECTOR Therapeutics, Inc. (EFTR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.